With 78% institutional ownership, Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst the big guns




  • In Business
  • 2022-10-02 11:01:40Z
  • By Simply Wall St.
 

If you want to know who really controls Bristol-Myers Squibb Company (NYSE:BMY), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 78% to be precise, is institutions. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute.

Let's take a closer look to see what the different types of shareholders can tell us about Bristol-Myers Squibb.

See our latest analysis for Bristol-Myers Squibb

What Does The Institutional Ownership Tell Us About Bristol-Myers Squibb?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Bristol-Myers Squibb already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Bristol-Myers Squibb's earnings history below. Of course, the future is what really matters.

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don't have a meaningful investment in Bristol-Myers Squibb. Looking at our data, we can see that the largest shareholder is The Vanguard Group, Inc. with 9.2% of shares outstanding. For context, the second largest shareholder holds about 8.0% of the shares outstanding, followed by an ownership of 4.4% by the third-largest shareholder.

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Bristol-Myers Squibb

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own less than 1% of Bristol-Myers Squibb Company. As it is a large company, we'd only expect insiders to own a small percentage of it. But it's worth noting that they own US$102m worth of shares. Arguably recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.

General Public Ownership

With a 21% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Bristol-Myers Squibb. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 3 warning signs for Bristol-Myers Squibb you should know about.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

COMMENTS

More Related News

Kratos Defense & Security Solutions (NASDAQ:KTOS) shareholders have endured a 54% loss from investing in the stock a year ago
Kratos Defense & Security Solutions (NASDAQ:KTOS) shareholders have endured a 54% loss from investing in the stock a year ago

The nature of investing is that you win some, and you lose some. Unfortunately, shareholders of Kratos Defense...

Recent uptick might appease Zebra Technologies Corporation (NASDAQ:ZBRA) institutional owners after losing 56% over the past year
Recent uptick might appease Zebra Technologies Corporation (NASDAQ:ZBRA) institutional owners after losing 56% over the past year

To get a sense of who is truly in control of Zebra Technologies Corporation ( NASDAQ:ZBRA ), it is important to...

Institutional owners may consider drastic measures as Enovix Corporation
Institutional owners may consider drastic measures as Enovix Corporation's (NASDAQ:ENVX) recent US$71m drop adds to long-term losses

Every investor in Enovix Corporation ( NASDAQ:ENVX ) should be aware of the most powerful shareholder groups. The group...

With 61% ownership, Julius Bär Gruppe AG (VTX:BAER) boasts of strong institutional backing
With 61% ownership, Julius Bär Gruppe AG (VTX:BAER) boasts of strong institutional backing

Every investor in Julius Bär Gruppe AG ( VTX:BAER ) should be aware of the most powerful shareholder groups. And the...

Individual investors account for 59% of Genesis Minerals Limited
Individual investors account for 59% of Genesis Minerals Limited's (ASX:GMD) ownership, while institutions account for 21%

Every investor in Genesis Minerals Limited ( ASX:GMD ) should be aware of the most powerful shareholder groups. We can...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business